Related Experiment Video
Updated: Oct 12, 2025
06:34
An Optimized Hemagglutination Inhibition HI Assay to Quantify Influenza-specific Antibody Titers
Published on: December 1, 2017
36.8K
Pfizer-BioNTech and Sinopharm: A Comparative Study on Post-Vaccination Antibody Titers
Rami Alqassieh1, Aiman Suleiman2, Sami Abu-Halaweh3
1Department of General and Specialized Surgery, Faculty of Medicine, The Hashemite University, Zarqa 13133, Jordan.
Vaccines
|November 27, 2021
Summary
The Pfizer-BioNTech COVID-19 vaccine generated higher IgG antibody titers than the Sinopharm vaccine in Jordanian adults. This suggests Pfizer-BioNTech offers superior quantitative efficiency, with Sinopharm recipients potentially benefiting from a booster dose.
Area of Science:
- Immunology
- Vaccinology
- Public Health
Background:
- COVID-19 vaccines stimulate immunity via diverse mechanisms.
- Understanding comparative antibody responses is crucial for vaccine efficacy assessment.
Purpose of the Study:
- To compare specific antibody titers between Pfizer-BioNTech and Sinopharm COVID-19 vaccine recipients.
- To evaluate the quantitative efficiency of two distinct COVID-19 vaccine platforms.
Main Methods:
- Prospective observational cohort study involving 288 Jordanian adults.
- Participants received two doses of either Pfizer-BioNTech or Sinopharm vaccine, 21 days apart.
- Serum IgG antibody titers were measured 6 weeks post-second dose.
Main Results:
- 99.3% of Pfizer-BioNTech recipients showed positive IgG titers versus 85.7% for Sinopharm (p < 0.001).
- Mean IgG titers were significantly higher in Pfizer-BioNTech recipients (515.5 BAU/mL) compared to Sinopharm recipients (170.0 BAU/mL) (p < 0.001).
- Pfizer-BioNTech vaccination strongly correlated with positive IgG titers (OR: 25.25).
Conclusions:
- Fully vaccinated individuals with the Pfizer-BioNTech vaccine demonstrated superior quantitative antibody response compared to Sinopharm.
- Consideration of a booster dose is recommended for Sinopharm recipients, particularly those with chronic immunosuppressive conditions.
